Logo Image
|Articles|February 19, 2016

Therapeutic Innovation & Regulatory Science: An Increasingly Global Approach

Author(s)DIA

How New Liberal Government Could Impact Health Care in Canada

After ten years of successive minority and/or majority Conservative leadership, Canada is now led by Prime Minister Justin Trudeau’s Liberal majority. A key component of the Liberal platform is the creation of a Chief Science Officer position to ensure that “scientific analyses are considered when the government makes decisions”; this renewed focus on evidence-based policy may be helpful to science-based industries across a number of sectors.

Read the article here. 

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more